This study represents the first clinical results for the usage of XB2001, an IL-1α-targeting monoclonal antibody (mAb), in humans, addressing the critical need for effective treatments in metastatic colorectal cancer (mCRC), particularly in chemo-resistant cases. The gene discussed is IL1A; the disease is metastatic colorectal cancer.